Complete abstract information will be provided to the CMSC Annual Meeting attendees on May 28, 2023.
| Year | ID | Type | Category | Title | Authors |
|---|
| 2018 | DX36 | Poster | Disease-Modifying Therapy |
Transition from Natalizumab to Dimethyl Fumarate in Multiple Sclerosis Patients: Clinical and MRI Outcomes |
Mark Waheed, DO, John W Rose, MD, Ka-ho Wong, BS, Stacey Clardy, MD PhD, Julia Klein, APRN, M. Mateo Paz Soldan, MD PhD, Lucy D Dewitt, MD and John Steffens, MD, Neurology, University of Utah School of Medicine, Salt Lake City, UT |
| 2018 | DX37 | Poster | Disease-Modifying Therapy |
Moderate-to-Vigorous Physical Activity Is Positively Associated with the Retinal Nerve Fibre Layer Thickness in Pediatric Multiple Sclerosis |
Alexander L Pearson, BA1, Stephanie A Grover, MSc, CCRP2, Danusha Nandamalavan, BSc, CCRA2, Tara Berenbaum, BSc3, Robert W Motl, PhD4, Marcia Finlayson, PhD, OT Reg (Ont), OTR5, Brenda Banwell, MD6 and E. Ann Yeh, MD, MA, FRCPC, Dip ABPN3, (1)Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada, (2)Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON, Canada, (3)Neurology, The Hospital for Sick Children, Toronto, ON, Canada, (4)Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (5)School of Rehabilitation Therapy, Queen’s University, Kingston, ON, Canada, (6)Children’s Hospital of Philadelphia, Philadelphia, PA |
| 2018 | DX38 | Poster | Disease-Modifying Therapy |
Life-Threatening Tumefactive Rebound of Multiple Sclerosis Following Fingolimod Discontinuation |
Mihir Kakara, M.D., Jay Kinariwala, M.D., Shitiz K Sriwastava, M.D. and Evanthia Bernitsas, MD, Neurology, Wayne State University School of Medicine, Detroit, MI |
| 2018 | DX39 | Poster | Disease-Modifying Therapy |
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis |
| 2018 | DX40 | Poster | Disease-Modifying Therapy |
An Update on Pregnancy Outcomes Following Ocrelizumab Treatment in Patients with Multiple Sclerosis and Other Autoimmune Diseases |
Sibyl Wray, MD1, Ludwig Kappos, MD2, Sandra Vukusic, MD, PhD3, Silvia Bader-Weder, MD4, Regine Buffels, MD4, Donna Masterman, MD, MS5, Julie Napieralski, PhD4 and Stephen L Hauser, MD6, (1)Sibyl Wray MD Neurology PC, Knoxville, TN, (2)Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Basel, Switzerland, (3)Service de Neurologie et Sclerose en Plaques, Fondation EDMUS pour la Sclerose en Plaques, Hopital Neurologique Pierre Wertheimer, Lyon, France, (4)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (5)Genentech Inc., South San Francisco, CA, (6)University of California, San Francisco, San Francisco, CA |
| 2018 | DX41 | Poster | Disease-Modifying Therapy |
Routine Laboratory Measures in the Controlled Treatment Period of Phase III Ocrelizumab Trials in Relapsing and Progressive Multiple Sclerosis |
| 2018 | DX42 | Poster | Disease-Modifying Therapy |
Prespecified Subgroup Analyses of Ocrelizumab Efficacy in Patients with Primary Progressive Multiple Sclerosis from the Phase III ORATORIO Study |
Jerry S Wolinsky, MD1, Xavier Montalban, MD, PhD2,3, Stephen L Hauser, MD4, Ludwig Kappos, MD5, Laura Julian, PhD6, Marianna Manfrini, MD PhD7, Shibeshih Belachew, MD, PhD7, Fabian Model, PhD7, Stanislas Hubeaux, MSc7 and Amit Bar-Or, MD8, (1)McGovern Medical School, UTHealth, Houston, TX, (2)Division of Neurology, University of Toronto, Toronto, ON, Canada, (3)Vall d’Hebron University Hospital, Barcelona, Spain, (4)University of California, San Francisco, San Francisco, CA, (5)University Hospital Basel, University of Basel, Basel, Switzerland, (6)Genentech, Inc., South San Francisco, CA, (7)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (8)University of Pennsylvania, Philadelphia, PA |
| 2018 | DX43 | Poster | Disease-Modifying Therapy |
Effect of Ocrelizumab on Vaccine Responses in Patients with Multiple Sclerosis |
Daniela Stokmaier, MSc Pharm PhD1, Kevin Winthrop, MD MPH2, Cathy Chognot, PhD3, Joanna Evershed, BSc4, Marianna Manfrini, MD PhD3, John McNamara, BSc MSc CStat5 and Amit Bar-Or, MD6, (1)F.Hoffmann-La Roche Ltd, Basel, Switzerland, (2)Division of Infectious Diseases, OHSU, Portland, OR, (3)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (4)Roche Products Ltd, Welwyn Garden City, United Kingdom, (5)John McNamara Consulting Limited, Cambridge, United Kingdom, (6)University of Pennsylvania, Philadelphia, PA |
| 2018 | DX44 | Poster | Disease-Modifying Therapy |
Pregnancy Outcomes in Patients with MS Treated with Teriflunomide: Postmarketing Data |
Patricia K Coyle, MD1, Sandra Vukusic, MD, PhD2, Stephanie Jurgensen, MPH3, Philippe Truffinet, MD4, Myriam Benamor, MD4, Elizabeth Poole, PhD3, Jeffrey Chavin, MD3 and Christina Chambers, PhD5, (1)Stony Brook University, Stony Brook, NY, (2)University Hospital of Lyon, Lyon, France, (3)Sanofi, Cambridge, MA, (4)Sanofi, Chilly-Mazarin, France, (5)University of California San Diego, La Jolla, CA |
| 2018 | DX45 | Poster | Disease-Modifying Therapy |
Brain MRI Activity and Atrophy in Ocrelizumab-Treated Relapsing Multiple Sclerosis Patients in the Open-Label Extension of the Pooled Opera Trials |
| 2018 | DX46 | Poster | Disease-Modifying Therapy |
Infusion-Related Reactions with Ocrelizumab in the Phase III Studies |
| 2018 | DX47 | Poster | Disease-Modifying Therapy |
Effect of Long-Term Teriflunomide Treatment on Lymphocyte Counts and Infection Rates in Pooled Data from TEMPSO, TOWER, and TOPIC Core and Extension Studies |
Aaron E Miller, MD1, Giancarlo Comi, MD2, Myriam Benamor, MD3, Philippe Truffinet, MD3, Karthinathan Thangavelu, PhD4, Jeffrey Chavin, MD4 and Mark S Freedman, MD5, (1)Icahn School of Medicine at Mount Sinai, New York, NY, (2)University Vita-Salute San Raffaele, Milan, Italy, (3)Sanofi, Chilly-Mazarin, France, (4)Sanofi, Cambridge, MA, (5)University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada |
| 2018 | DX48 | Poster | Disease-Modifying Therapy |
Effect of Teriflunomide on Substantial Disability Worsening in Patients with Relapsing Forms of MS in the Phase 3 TOWER Study |
Mark S Freedman, MD1, Aaron E Miller, MD2, Elizabeth Poole, PhD3, Jeffrey Chavin, MD3, Philippe Truffinet, MD4 and Ludwig Kappos, MD5, (1)University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, (2)Icahn School of Medicine at Mount Sinai, New York, NY, (3)Sanofi, Cambridge, MA, (4)Sanofi, Chilly-Mazarin, France, (5)Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Basel, Switzerland |
| 2018 | DX50 | Poster | Disease-Modifying Therapy |
Ocrelizumab Pregnancy Registry to Assess Maternal, Fetal and Infant Outcomes in Women with Multiple Sclerosis Exposed to Ocrelizumab during Pregnancy |
David Wormser, MSc, MPhil PhD1, Pierre Engel, PharmD, MPH, PhD2, Kristen Hahn, MPH, PhD3, Silvia Bader-Weder, MD1, Eva-Maria Didden, PhD1, Joanna Evershed, BSc4, Monika Garas, PhD1, Qing Wang, PhD1 and Kerstin Hellwig, PhD MD5, (1)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (2)QuintilesIMS, Paris, France, (3)QuintilesIMS, Cambridge, MA, (4)Roche Products Ltd, Welwyn Garden City, United Kingdom, (5)St. Josef-Hospital, Ruhr University, Bochum, Germany |
| 2018 | DX51 | Poster | Disease-Modifying Therapy |
Post-Marketing Study to Evaluate Pregnancy and Infant Outcomes in Women with Multiple Sclerosis Exposed to Ocrelizumab during Pregnancy |
Andrea V Margulis, MD ScD1, Elizabeth B Andrews, PhD MPH2, Sonia Hernandez-Diaz, MD DrPH3, Melinda Magyari, MD PhD4, Elena Rivero-Ferrer, MD MPH1, Silvia Bader-Weder, MD5, Joanna Evershed, BSc6, Monika Garas, PhD5, Qing Wang, PhD5 and David Wormser, MSc, MPhil PhD5, (1)RTI Health Solutions, Barcelona, Spain, (2)RTI Health Solutions, Research Triangle Park, NC, (3)Harvard University, Boston, MA, (4)Danish Multiple Sclerosis Center, Copenhagen University Hospital, Copenhagen, Denmark, (5)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (6)Roche Products Ltd, Welwyn Garden City, United Kingdom |
| 2018 | DX52 | Poster | Disease-Modifying Therapy |
Efficacy Outcomes in Patients Randomized to Fingolimod or Injectable Disease-Modifying Therapies in PREFERMS: Effect of Previous Treatment Cycles |
Samuel F Hunter, MD1, Florian P Thomas, MD, PhD, MA2,3, Xiangyi Meng, PhD4, Lesley Schofield, PhD4, Scott Kolodny, MD4, Nadia Tenenbaum, MD4 and Bruce AC Cree, MD, PhD5, (1)Advanced Neurosciences Institute, Franklin, TN, (2)Seton Hall-Hackensack Meridian School of Medicine, South Orange, NJ, (3)Neurology, Hackensack University Medical Center, Hackensack, NJ, (4)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (5)UCSF Neurology, Weill Institute for Neurosciences, San Francisco, CA |
| 2018 | DX53 | Poster | Disease-Modifying Therapy |
Changes in Whole Brain Volume and Cortical Gray Matter over 2 Years of Natalizumab Treatment: Results from the STRIVE Study |
Jai Perumal, MD1, Robert J Fox, MD2, Roumen Balabanov, MD3, Laura J Balcer, MD, MSCE4, Steven Galetta, MD4, Shavy Makh, MPhil5, Sourav Santra, PhD5, Elizabeth Fisher, PhD5, Christophe Hotermans, MD, PhD5 and Lily Lee, MD5, (1)Judith Jaffe Multiple Sclerosis Center, New York, NY, (2)Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, (3)Northwestern University, Chicago, IL, (4)New York University Langone Medical Center, New York, NY, (5)Biogen, Cambridge, MA |
| 2018 | DX54 | Poster | Disease-Modifying Therapy |
Review of Immunization Status of Patients Switched to Ocrelizumab: A Tertiary Care Experience |
Lakshman Arcot Jayagopal, MD, Deb Cramer, RN, BSN, MSCN, Wendy Durand, RN BSN, Deborah Gallaro, RPH, Bren Hammond, RN, BSN, MSCN, Michael Persenaire, MD, Gary Stobbe, MD, Jennie Toro, RN, Gloria von Geldern, MD and Annette Wundes, MD, University of Washington, Seattle, WA |
| 2018 | DX55 | Poster | Disease-Modifying Therapy |
Real-World Characterization of Flu-like Symptom Severity and Duration in Patients with RMS: Interim Analysis of the Peginterferon Beta-1a Pop Study |
Maria L Naylor, PhD1, Marco Salvetti, MD2, Jang Yun, MS, PhD1, Craig Wakeford, MA1 and Sibyl Wray, MD3, (1)Biogen, Cambridge, MA, (2)Sapienza University, Sant’ Andrea Hospital, Rome, Italy, (3)Hope Neurology MS Center, Knoxville, TN |
| 2018 | DX56 | Poster | Disease-Modifying Therapy |
The Importance of Pharmacist Involvement in Laboratory Adherence for Patients on Disease Modifying Therapy for Multiple Sclerosis, Utilizing a Clinical Dashboard |
Dante M Grassi, Pharm D., BCPS, Enterprise Pharmacy, Center for Pharmacy Innovation and Outcomes, Geisinger, Danville, PA, Amanda Sharry-Rogers, Pharm D., BCPS, Enterprise Pharmacy, Geisinger, Wilkes-Barre, PA, Ashley L Lauver, Pharm D., Enterprise Pharmacy, Geisinger, Danville, PA, Douglas C Nathanson, MD, Neuroscience, Geisinger, Wilkes-Barre, PA, Joseph J Chronowski, MBA, BA, Care Support Services, Geisinger, Danville, PA and Jove Graham, PhD, Center for Pharmacy Innovation and Outcomes, Geisinger, Danville, PA |
| 2018 | DX57 | Poster | Disease-Modifying Therapy |
Potential Infectious Complications of B-Cell Depleting Therapies-a Focus on Rituximab in Multiple Sclerosis |
Cindy Darius, MS, RN1, Maureen A. Mealy, PhD(c), RN2, Megan Esch, MD3, Salman Aljarallah, MBBS FRCPC4, Kathleen Costello, MS, ANP-BC, MSCN5, Lisa Fox, PA-C MPAS4 and Shiv Saidha, MBBCh6, (1)Neurology, Johns Hopkins School of Medicine, Balitmore, MD, (2)Acute and Chronic Care, Johns Hopkins University School of Nursing, Baltimore, MD, (3)Neurology, The Johns Hopkins School of Medicine, Baltimore, MD, (4)Neurology, Johns Hopkins School of Medicine, Baltimore, MD, (5)Vice President, Healthcare Access, National Multiple Sclerosis Society, New York, NY, (6)Neurology, Johns Hopkins University, Baltimore, MD |
| 2018 | DX58 | Poster | Disease-Modifying Therapy |
Baseline Cognitive Function of Patients with Relapsing Remitting Multiple Sclerosis Is Associated with Therapeutic Response to Natalizumab |
Daniel Golan, MD1, Mark Gudesblatt, MD2, Karl Wisseman, N/A2, Myassar Zarif, MD2, Barbara Bumstead, MS, ANCP, MSCN2, Lori Fafard, RN, BSN, CNRN, MSCN, CCRP2, Cynthia Sullivan, PhD3, Jeffrey Wilken, PhD4, Jared Srinivasan, N/A2, Karen Blitz, DO2, Marijean Buhse, PhD, NP, RN, MSCN5 and Glen Doniger, PhD6, (1)Rapparport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, (2)South Shore Neurologic Associates, Patchogue, NY, (3)Nursing, State University of New York @ Stony Brook, Stony Brook, NY, (4)Washington Neuropsychology Research Group, Washington, DC, (5)Stony Brook University, Stony Brook, NY, (6)NeuroTrax Corporation, Modiin, Israel |
| 2018 | DX59 | Poster | Disease-Modifying Therapy |
Characterization of the Hispanic MS Patient on Alemtuzumab |
Angel Chinea, MD1, Ivonne Vicente, MD2, Cristina M Rubi, BS2, Allan J Reyes, BA3, Astrid Diaz, BS4 and Genesis Burgos, HS5, (1)San Juan Multiple Sclerosis Center, San Juan, PR, (2)San Juan Multiple Sclerosis Center, Guaynabo, PR, (3)Neurology, San Juan MS Center, Guaynabo, PR, Puerto Rico, (4)San Juan MS Center, Guaynabo, PR, (5)San Juan MS Center, Guaynabo, PR, Puerto Rico |
| 2018 | DX60 | Poster | Disease-Modifying Therapy |
Leflunomide for the Treatment of Multiple Sclerosis: A Case Series |
Daniel Kantor, MD1,2, Asya I. Wallach, MD3, Samuel F Hunter, MD4, Christopher W. Milligan, MS, PA-C4, Ajay S Gupta, MD5, Richard A. Sater, MD, PhD6, Marcus Rice, MD7 and Ilya Kister, MD3, (1)Medical Partnership 4 MS (MP4MS), Coconut Creek, FL, (2)Florida Atlantic University, Boca Raton, FL, (3)MS Comprehensive Care Center, NYU School of Medicine, New York, NY, (4)Advanced Neurosciences Institute, Franklin, TN, (5)Fort Wayne Neurological Center, Fort Wayne, IN, (6)Guilford Neurological Associates, Greensboro, NC, (7)Neurology Specialists, Norfolk, VA |
| 2018 | DX61 | Poster | Disease-Modifying Therapy |
Fingolimod and Cryptococcus: A Reminder of the Intersection between Immunomodulation and Infectious Disease |
Rohini D Samudralwar, MD and Ann Cross, MD, Neurology, Washington University in St. Louis, St.Louis, MO |
| 2018 | DX62 | Poster | Disease-Modifying Therapy |
6 Month Results from a Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS), Demonstrates Complete Elimination of Gd-Enhancing Lesions |
Matilde Inglese, MD, PhD1, Maria Petracca, MD, PhD2, Sirio Cocozza, MD2, Sibyl Wray, MD3, Michael K Racke, MD4, Richard Shubin, MD5, Cary L Twyman, MD6, Wendy Su, PhD7, James Eubanks, PhD7, Koby Mok, PhD7, Michael Weiss, JD7 and Edward J. Fox, MD, PhD8, (1)Department of Neurology, Radiology and Neuroscience, Mount Sinai School of Medicine, New York, NY, (2)Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, (3)Hope Neurology MS Center, Knoxville, TN, (4)Wexner Medical Center, Ohio State University, Columbus, OH, (5)SC3 Research Group, Inc, Pasadena, CA, (6)Associates in Neurology PSC, Lexington, KY, USA, Lexington, KY, (7)Autoimmune, TG Therapeutics, Inc, New York, NY, (8)Central Texas Neurology Consultants, Round Rock, TX |
| 2018 | DX63 | Poster | Disease-Modifying Therapy |
Myelin Water Fraction As a Potential Marker of Progression in Primary Progressive Multiple Sclerosis |
Kimberley Chang, .1, Irene Vavasour, PhD1, Roger Tam, .1, David Clayton, .2, Victoria Levesque, PhD2, David Li, MD, FRCPC1, Anthony Traboulsee, MD1 and Shannon Kolind, PhD1, (1)University of British Columbia, Vancouver, BC, Canada, (2)Genentech, Inc., South San Francisco, CA |
| 2018 | EG01 | Poster | Epidemiology and Genetics |
National Estimates of Self-Reported Sitting Time in Adults with Multiple Sclerosis |
Jeffer E Sasaki, PhD1, Robert W Motl, PhD1, Gary Cutter, PhD2, Ruth A Marrie, PhD3, Tuula Tyry, PhD4 and Amber Salter, PhD5, (1)Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (2)University of Alabama at Birmingham, Birmingham, AL, (3)Department of Internal Medicine (Neurology), University of Manitoba, Winnipeg, MB, Canada, (4)Dignity Health, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, (5)Washington University in St Louis, St Louis, MO |
| 2018 | EG02 | Poster | Epidemiology and Genetics |
Validity of the Marshall Sitting Questionnaire in Persons with Multiple Sclerosis |
Jeffer E Sasaki, PhD1, Robert W Motl, PhD1 and Edward McAuley, PhD2, (1)Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (2)Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL |
| 2018 | EG03 | Poster | Epidemiology and Genetics |
Factors Associated with Excessive Sitting Time in Multiple Sclerosis |
Jeffer E Sasaki, PhD1, Robert W Motl, PhD1, Gary Cutter, PhD2, Ruth A Marrie, PhD3, Tuula Tyry, PhD4 and Amber Salter, PhD5, (1)Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (2)University of Alabama at Birmingham, Birmingham, AL, (3)Department of Internal Medicine (Neurology), University of Manitoba, Winnipeg, MB, Canada, (4)Dignity Health, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, (5)Washington University in St Louis, St Louis, MO |
| 2018 | EG04 | Poster | Epidemiology and Genetics |
Prevalence of Comorbidities in Patients with and without Multiple Sclerosis By Age and Sex: A US Retrospective Claims Database Analysis |
Kiren Kresa-Reahl, MD, dence Multiple Sclerosis Center and Providence Center for Parkinson’s Disease, Portland, OR, Natalie C Edwards, MSc, Health Services Consulting Corporation, Boxborough, MA and Amy L Phillips, PharmD, EMD Serono, Inc., Rockland, MA |
| 2018 | EG05 | Poster | Epidemiology and Genetics |
Mood Disorders in Multiple Sclerosis: About 100 Patients Collected in the Service of Neurology University Hospital of Tlemcen (ALGERIA) |
Bouchenak Khelladi Djaouad Sr., Professor, Neurology, University of Medecine, Tlemcen, Algeria |
| 2018 | EG06 | Poster | Epidemiology and Genetics |
The Current Situation of the Multiple Sclerosis in the Department of Tlemcen (ALGERIA) |
Bouchenak Khelladi Djaouad Sr., Professor, Neurology, University of Medecine, Tlemcen, Algeria |
| 2018 | EG07 | Poster | Epidemiology and Genetics |
Epidemiological Evaluation of People with Multiple Sclerosis in Brazil |
Ana Maria Canzonieri, psychologist1, Thais Mira Simandi, Psychology student2 and Dyana Gervana de Oliveira Fernandes, biomedicine student1, (1)Pesquisa cientifica, ABEM – Brazilian Association of Multiple Sclerosis, Sao Paulo, Brazil, (2)Pesquisa cientifica, ABEM – Brazilian Association of Multiple Sclerosis, sAO pAULO, Brazil |
| 2018 | EG08 | Poster | Epidemiology and Genetics |
Validation of the Symptomscreen with Objective Clinical Outcome Measures |
Kathryn C Fitzgerald, ScD, Johns Hopkins School of Medicine, Baltimore, MD, Amber Salter, PhD, Washington University in St Louis, St Louis, MO, Tuula Tyry, PhD, Dignity Health, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, Robert J Fox, MD, Cleveland Clinic, Cleveland, OH, Gary Cutter, PhD, University of Alabama at Birmingham, Birmingham, AL and Ruth Ann Marrie, MD, PhD, University of Manitoba, Winnipeg, MB, Canada |
| 2018 | EG09 | Poster | Epidemiology and Genetics |
Overview of the North American Registry for Care and Research in MS (NARCRMS) |
Kottil Rammohan, MD1, David Jones, MD2, June Halper, MSN, ANP, FAAN3, Sara McCurdy Murphy, BA4 and Lisa Patton, BA4, (1)University of Miami, Miami, FL, (2)UVA, Charlottesville, VA, (3)CEO-CMSC, Hackensack, NJ, (4)CRB, Social & Scientific Systems, Inc., Silver Spring, MD |
| 2018 | ET01 | Poster | Ethics |
Professionals’ Knowledge and Attitudes about End of Life in MS |
Aliza Ben-Zacharia, DNP, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, Francois Bethoux, MD, Department of Rehabilitation Services, Cleveland Clinic Mellen Center, Cleveland, OH and Angelo Volandes, MD, MPH, Palliative Care, Co-Founder & President ACP Decisions, Harvard School of Medicine, Boston, MA |
| 2018 | ET02 | Poster | Ethics |
Engaging Minorities with MS in Research: How Patients Learn about and Consider Research Participation |
Hollie Schmidt, MS1, Debra I Frankel, MS OTR2, April Moreno, PhD MPA3, Mitzi J Williams, MD4, Lilyana Amezcua, MD, MS5, Shawn Feliciano, B.S.1, Anita Williams, M.S.1, Daniel Machemer, PhD6, Terrie Livingston, PharmD7, Monique LaRocque, MPH8, Melissa Glim, MPH8 and Daniela Pimentel Maldonado, MD9, (1)Accelerated Cure Project for MS, Waltham, MA, (2)Advocacy, Services and Research Department, National Multiple Sclerosis Society, NY, NY, (3)Biomedical Informatics, UCSD School of Medicine, La Jolla, CA, (4)Multiple Sclerosis Center of Atlanta, Atlanta, GA, (5)Neurology, University of Southern California, Los Angeles, CA, (6)Genentech, Inc., South San Francisco, CA, (7)Biogen, Weston, MA, (8)Feinstein Kean Healthcare, Washington, DC, (9)University of Massachusetts Medical School, Worcester, MA |
| 2018 | FC01 | Poster | Family and Caregivers |
An Exploratory Study of the Benefit of an Emotionally Focused Therapy Program on the Relationship Quality of Couples Living with Multiple Sclerosis (MS) |
Deborah S Lockridge, RN, BSN, MMFT, Norton Healthcare, Louisville, KY |
| 2018 | FC02 | Poster | Family and Caregivers |
Identifying the Unmet Needs of Adults with Multiple Sclerosis (MS) Experiencing Cognitive Difficulties and Their Support Partners. |
Elizabeth J Halstead, Ph.D, MyHealios, Flemington, NJ, United Kingdom; Health and Social Care, University of Sunderland, London, United Kingdom, Damian Fiore, Pharm.D, Genentech Inc., San Francisco, CA and Kim T Mueser, Ph.D, Center for Psychiatric Rehabilitation, Boston University, Boston, MA; MyHealios, Flemington, NJ |